GSK's Hibsago Receives FDA Approval for Chronic Hepatitis B Treatment

AI-generated NewsSnap summary based on source reporting.
Published: 2026-10-21
Category: health
Source: DirectorsTalk Interviews (citing GSK)

GSK's drug, Hibsago (bepirovirsen), has received FDA approval for treating chronic hepatitis B. Phase III trials demonstrated a 19% functional cure rate after six months, offering a new therapeutic option for patients. This approval marks a significant advancement in managing a widespread global health condition.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai